Comparison of Outcomes Between Low Dose Emicizumab and Extended Half-life Factor VIII With Pharmacokinetic-guided Prophylaxis in Clinically Severe Hemophilia A
Latest Information Update: 17 Feb 2025
At a glance
- Drugs Emicizumab (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- 01 Jan 2025 Results assessing low-dose emicizumab versus low-/intermediate-dose factor VIII for prevention of bleeding, joint health and QoL in patients with noninhibitor severe HA or moderate HA with severe bleeding phenotype, published in the Haemophilia.
- 04 Mar 2024 Planned primary completion date changed from 21 Feb 2024 to 21 Mar 2024.
- 07 Dec 2023 New trial record